The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Extract from Annual report for year ended 31st December 2021 - published 30th June 2022
"The Group remains well capitalised with cash and cash equivalents of £15.7m as at 31 December 2021."
Extract from ST's alpha recent report
"Net debt £15.8mn (30 June 2022)"
Looks as if Simon is muddling debt with cash and cash equivalents!
I am the Chief Scientific Officer for Avacta Therapeutics, headquartered in?Scale Space, White City.? Avacta is a biotechnology company developing a portfolio of clinical and pre-clinical staged assets for the treatment of cancer.? We have two technology platforms, the first is called pre|CISIONTM.? The technology delivers a drug which is much better tolerated, enabling further treatment cycles to be administered.
https://www.imperial.ac.uk/white-city-campus/impact/spotlight/fiona-mclaughlin/
July 2022 interview - note last sentence in the above extract! Not exactly new news...
"Post-period end, in August 2022, the third cohort was completed and the SDMC approved dose escalation to 200mg/m2 in the fourth cohort which is now recruiting patients in the UK. The fourth cohort is expected to be completed during Q4 2022."
The above from https://www.londonstockexchange.com/news-article/AVCT/interim-results-for-the-period-ended-30-june-2022/15649319
For AVA6000 Phase I Design and Timeline, see page 25 of https://avacta.com/wp-content/uploads/2022/05/ARA-2021.pdf
"Approximately 4 cohorts of 3-5 patients per cohort ..."
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce positive headline results from its ovarian cancer clinical verification study, demonstrating that a Parsortix® blood test can be used to determine if a woman is at risk of a malignant pelvic mass. Following the recent FDA clearance and CE Marking of the Parsortix PC1 system for use in metastatic breast cancer, this achievement marks another important milestone in the Company's commercialisation strategy.
https://www.londonstockexchange.com/news-article/AGL/positive-headline-results-from-ovarian-study/15649308
"It is a great pleasure to report a record interim financial performance for the first half of 2022, with EBITDA up 16% and FCF up 7% period on period. These results reflect increased metal prices to some extent counteracted by inflationary pressures but notwithstanding this, our costs during H1 2022 were well controlled with increases mitigated by weaker operating currencies and a fixed price electricity contract at Sasa. We are therefore delighted to declare an interim dividend of 10 pence per share."
NB "..fixed price electricity contract at Sasa.."
Molar mass doxorubicin is 544 g/mol
Molar mass of AVA6000 is 832 g/mol
max permitted dose of doxorubicin is 60-75 mg/m2
so the C4 dose of AVA6000 at 200 mg/m2 is about twice the average permitted dose - that is very significent!
Thanks - useful find - CFO's "View from the Bridge". First para:-
"As we continue to scale up operations of each portfolio company, we are hoping to communicate more updates via less formal communication methods. With so much going on, we think it’s good to provide an occasional update on background of “behind the scenes” and our own analysis of different developments in a less “RNS-like” fashion. It has been a busy summer and we have accomplished quite a lot as a group."
https://www.londonstockexchange.com/news-article/market-news/result-of-secondary-placing-of-shares-in-darktrace/15426499
https://www.londonstockexchange.com/news-article/market-news/results-of-secondary-placing-in-darktrace-plc/15197528
https://www.londonstockexchange.com/news-article/market-news/result-of-placing-of-existing-shares-in-darktrace/15156817
https://www.londonstockexchange.com/news-article/market-news/result-of-placing-of-existing-shares-in-darktrace/15088411
Can someone point to where in the IPO statement it states that the warrants were valued at $0.9 each??
https://www.sec.gov/Archives/edgar/data/1808377/000182912622015921/innovativeeyewear_424b4.htm
https://www.londonstockexchange.com/news-article/TEK/lucyd-pricing-of-us-7-35-million-ipo/15584306
"...pricing of its initial public offering of 980,000 units consisting of 980,000 shares of its common stock and accompanying warrants to purchase up to 1,960,000 shares of common stock. Each share of common stock is being sold together with two Warrants, with each warrant exercisable for one share of common stock, at a combined offering price of US$7.50, for gross proceeds of approximately US$7.35 million,..."
"..We have granted a 45-day option to the representative of the underwriters to purchase up to 147,000 additional shares of common stock at a price of $7.48 per share and/or up to an additional 294,000 Warrants to purchase up to 294,000 shares of common stock at a price per Warrant of $0.01.."
Now 30% down on the IPO price
https://www.cnbc.com/quotes/LUCY
This decree is about investors selling shares. It is not about a company, eg AMC, selling its resource.
https://www.reuters.com/markets/europe/russia-bans-western-investors-selling-stakes-banks-key-assets-including-sakhakin-2022-08-05/
Try this
https://www.nasdaq.com/market-activity/ipos/financial-filings?dealId=1121064-101505
and scroll down to the 07/25/2022 link